DADC
GSK icon

D.A. Davidson & Co’s GSK GSK Stock Holding History

D.A. Davidson & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Sell
71,423
-30,263
-30% -$1.6M 0.02% 519
2026
Q1 		$5.61M Buy
101,686
+28,362
+39% +$1.54M 0.03% 371
2025
Q4 		$3.6M Buy
73,324
+494
+0.7% +$23K 0.02% 480
2025
Q3 		$3.14M Buy
72,830
+2,657
+4% +$104K 0.02% 500
2025
Q2 		$2.69M Sell
70,173
-18,865
-21% -$721K 0.02% 519
2025
Q1 		$3.45M Buy
89,038
+1,191
+1% +$43.6K 0.03% 402
2024
Q4 		$2.97M Sell
87,847
-14,808
-14% -$533K 0.02% 444
2024
Q3 		$4.2M Sell
102,655
-1,916
-2% -$78.4K 0.03% 368
2024
Q2 		$4.02M Sell
104,571
-27,185
-21% -$1.14M 0.04% 353
2024
Q1 		$5.65M Buy
131,756
+2,433
+2% +$100K 0.05% 276
2023
Q4 		$4.79M Sell
129,323
-73
-0.1% -$2.62K 0.05% 298
2023
Q3 		$4.69M Sell
129,396
-3,243
-2% -$115K 0.05% 280
2023
Q2 		$4.73M Sell
132,639
-2,154
-2% -$77.3K 0.05% 273
2023
Q1 		$4.79M Buy
134,793
+10,371
+8% +$363K 0.05% 259
2022
Q4 		$4.37M Buy
124,422
+5,440
+5% +$181K 0.05% 277
2022
Q3 		$3.5M Sell
118,982
-27,283
-19% -$1.03M 0.05% 292
2022
Q2 		$7.96M Buy
146,265
+23,600
+19% +$1.3M 0.1% 164
2022
Q1 		$6.68M Buy
122,665
+2,347
+2% +$127K 0.07% 216
2021
Q4 		$6.63M Sell
120,318
-1,580
-1% -$82.2K 0.07% 228
2021
Q3 		$5.82M Sell
121,898
-14,758
-11% -$741K 0.07% 234
2021
Q2 		$6.8M Sell
136,656
-41,159
-23% -$1.98M 0.08% 201
2021
Q1 		$7.93M Buy
177,815
+15,395
+9% +$699K 0.1% 157
2020
Q4 		$7.48M Sell
162,420
-15,230
-9% -$700K 0.11% 140
2020
Q3 		$8.36M Sell
177,650
-4,126
-2% -$207K 0.15% 114
2020
Q2 		$9.27M Sell
181,776
-27,653
-13% -$1.42M 0.17% 95
2020
Q1 		$9.91M Buy
209,429
+16,493
+9% +$880K 0.19% 91
2019
Q4 		$11.3M Buy
192,936
+3,265
+2% +$182K 0.18% 96
2019
Q3 		$10.1M Sell
189,671
-572
-0.3% -$29.4K 0.18% 98
2019
Q2 		$9.52M Buy
190,243
+5,794
+3% +$291K 0.18% 95
2019
Q1 		$9.56M Buy
184,449
+9,276
+5% +$464K 0.16% 105
2018
Q4 		$8.37M Sell
175,173
-26,910
-13% -$1.33M 0.16% 103
2018
Q3 		$10.1M Buy
202,083
+64,621
+47% +$3.28M 0.18% 96
2018
Q2 		$6.93M Buy
137,462
+6,000
+5% +$302K 0.14% 128
2018
Q1 		$6.42M Buy
131,462
+7,744
+6% +$361K 0.13% 133
2017
Q4 		$5.49M Sell
123,718
-10,005
-7% -$462K 0.12% 150
2017
Q3 		$6.79M Sell
133,723
-395
-0.3% -$20K 0.13% 159
2017
Q2 		$7.23M Sell
134,118
-220
-0.2% -$11.7K 0.16% 114
2017
Q1 		$7.08M Sell
134,338
-36,205
-21% -$1.84M 0.17% 107
2016
Q4 		$8.2M Buy
170,543
+25,820
+18% +$1.28M 0.19% 111
2016
Q3 		$7.8M Buy
144,723
+32,164
+29% +$1.76M 0.19% 115
2016
Q2 		$6.09M Buy
112,559
+22,685
+25% +$1.2M 0.18% 114
2016
Q1 		$4.55M Sell
89,874
-14,843
-14% -$739K 0.14% 142
2015
Q4 		$5.28M Sell
104,717
-18
-0% -$917 0.17% 129
2015
Q3 		$5.03M Buy
104,735
+7,729
+8% +$402K 0.18% 122
2015
Q2 		$5.05M Buy
97,006
+44,964
+86% +$2.53M 0.17% 129
2015
Q1 		$3M Buy
52,042
+10,223
+24% +$586K 0.1% 208
2014
Q4 		$2.23M Buy
41,819
+10,673
+34% +$597K 0.07% 253
2014
Q3 		$1.79M Buy
31,146
+209
+0.7% +$12.8K 0.06% 287
2014
Q2 		$2.06M Buy
30,937
+1,550
+5% +$105K 0.07% 267
2014
Q1 		$1.96M Sell
29,387
-323
-1% -$21.8K 0.07% 272
2013
Q4 		$1.98M Buy
29,710
+3,613
+14% +$234K 0.07% 253
2013
Q3 		$1.63M Buy
26,097
+959
+4% +$61.7K 0.07% 255
2013
Q2 		$1.57M Buy
+25,138
New +$1.6M 0.08% 246

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.A. Davidson & Co's GSK Position: Q2 2026 in Review

D.A. Davidson & Co reduced its GSK (GSK) stake by 30% in Q2 2026, selling an estimated $1.6M and leaving 71,423 shares worth $3.74M. The position accounts for 0.02% of the portfolio, ranked #519.

D.A. Davidson & Co first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $11.3M in Q4 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • D.A. Davidson & Co held 71,423 shares of GSK worth $3.74M as of Q2 2026.
  • D.A. Davidson & Co sold 30,263 GSK shares in Q2 2026, an estimated $1.6M.
  • GSK made up 0.02% of D.A. Davidson & Co's portfolio in Q2 2026, its #519 holding.
  • D.A. Davidson & Co first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • D.A. Davidson & Co's GSK position peaked at $11.3M in Q4 2019.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.